These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 23417352)

  • 41. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study.
    Lal R; Sukbuntherng J; Luo W; Chen D; Blumenthal R; Ho J; Cundy KC
    Clin Ther; 2012 Jan; 34(1):201-13. PubMed ID: 22206794
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
    Gretler DD; Guerciolini R; Williams PJ
    Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics and Tolerability of Zibotentan in Patients with Concurrent Moderate Renal and Moderate Hepatic Impairment.
    Mercier AK; Sunnåker M; Ueckert S; Pawlik T; Henricson E; Molodetskyi O; Law GC; Parker VER; Oscarsson J
    Clin Pharmacokinet; 2023 Dec; 62(12):1713-1724. PubMed ID: 37801266
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vilazodone for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2012 Apr; 66(4):356-68. PubMed ID: 22284853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics, safety, and tolerability of maraviroc in HIV-negative subjects with impaired renal function.
    Vourvahis M; Fang J; Checchio T; Milton A; Weatherley B; McFadyen L; Heera J
    HIV Clin Trials; 2013; 14(3):99-109. PubMed ID: 23835512
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The pharmacokinetics and safety of darapladib in subjects with severe renal impairment.
    Magee MH; Shaddinger B; Collins D; Siddiqi S; Soffer J
    Br J Clin Pharmacol; 2015 Oct; 80(4):654-61. PubMed ID: 25953363
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment : phase I, open-label, parallel-group, single-dose, single-centre study.
    Padhi D; Harris RZ; Salfi M; Noveck RJ; Sullivan JT
    Clin Drug Investig; 2008; 28(10):635-43. PubMed ID: 18783302
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of moderate liver impairment on the pharmacokinetics of opicapone.
    Rocha JF; Santos A; Falcão A; Lopes N; Nunes T; Pinto R; Soares-da-Silva P
    Eur J Clin Pharmacol; 2014 Mar; 70(3):279-86. PubMed ID: 24271646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics, Tolerability, and Safety of Esmethadone in Subjects with Chronic Kidney Disease or Hepatic Impairment.
    Ferri N; De Martin S; Stuart J; Traversa S; Mattarei A; Comai S; Folli F; Pappagallo M; Guidetti C; Inturrisi CE; Manfredi PL
    Drugs R D; 2024 Jun; 24(2):341-352. PubMed ID: 39095578
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects.
    Shin D; Lee S; Yi S; Yoon SH; Cho JY; Bahng MY; Jang IJ; Yu KS
    Drug Des Devel Ther; 2017; 11():713-723. PubMed ID: 28331291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
    Groenendaal-van de Meent D; Adel MD; Noukens J; Rijnders S; Krebs-Brown A; Mateva L; Alexiev A; Schaddelee M
    Clin Drug Investig; 2016 Sep; 36(9):743-751. PubMed ID: 27352308
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
    Cass LM; Efthymiopoulos C; Marsh J; Bye A
    Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
    Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized, double-blind, placebo-controlled, 8-week study of vilazodone, a serotonergic agent for the treatment of major depressive disorder.
    Khan A; Cutler AJ; Kajdasz DK; Gallipoli S; Athanasiou M; Robinson DS; Whalen H; Reed CR
    J Clin Psychiatry; 2011 Apr; 72(4):441-7. PubMed ID: 21527122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.
    Sidharta PN; Ulč I; Dingemanse J
    Clin Drug Investig; 2019 Nov; 39(11):1117-1123. PubMed ID: 31435905
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vilazodone for the treatment of major depressive disorder.
    Iranikhah M; Wensel TM; Thomason AR
    Pharmacotherapy; 2012 Oct; 32(10):958-65. PubMed ID: 23033234
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of vilazodone in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
    Croft HA; Pomara N; Gommoll C; Chen D; Nunez R; Mathews M
    J Clin Psychiatry; 2014 Nov; 75(11):e1291-8. PubMed ID: 25470094
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.